In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Additional round brings $20mm to BiPar Sciences

Executive Summary

Cancer drug developer BiPar Sciences raised $20mm through an additional financing round. Returning investors included Domain Associates, Canaan Partners, Vulcan Capital, PolyTechnos Venture-Partners, Asset Management Co., Quantum Technology Partners, and Lighthouse Capital Partners, which provided venture debt. BiPar will use the proceeds to advance its lead program BSI201 into Phase III trials for breast cancer.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Nonconvertible Debt
    • Private Placement

Related Companies

UsernamePublicRestriction

Register